# An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC

> **NCT06894511** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 7 (actual)

## Conditions studied

- Metastatic Castration Resistant Prostate Cancer (mCRPC)

## Interventions

- **DRUG:** AAA617
- **DRUG:** ARPI: Abiraterone
- **DRUG:** ARPI: Enzalutamide

## Key facts

- **NCT ID:** NCT06894511
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-09-11
- **Primary completion:** 2026-10-15
- **Final completion:** 2026-10-15
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06894511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06894511, "An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06894511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*